DGM
Darwin Global Management Portfolio holdings
AUM
$2.38B
This Quarter Return
+22.08%
1 Year Return
+81.43%
3 Year Return
+6,053.69%
5 Year Return
–
10 Year Return
–
AUM
$1.23B
AUM Growth
+$1.23B
(+43%)
Cap. Flow
+$253M
Cap. Flow
% of AUM
20.56%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
10
New
1
Increased
2
Reduced
2
Closed
5
Top Buys
| 1 |
Insmed
INSM
|
$508M |
| 2 |
Summit Therapeutics
SMMT
|
$23.8M |
| 3 |
Vaxcyte
PCVX
|
$13.4M |
Top Sells
| 1 |
Cytokinetics
CYTK
|
$246M |
| 2 |
Corbus Pharmaceuticals
CRBP
|
$14.3M |
| 3 |
Spyre Therapeutics
SYRE
|
$10.3M |
| 4 |
Geron
GERN
|
$8.52M |
| 5 |
Avidity Biosciences
RNA
|
$8.11M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $766M | 62.31% | 10,497,277 +6,956,182 | +196% | +$508M |
|
|
2
Vaxcyte
PCVX
$4B
| $251M | 20.43% | 2,198,187 +117,241 | +6% | +$13.4M |
|
|
3
Geron
GERN
$893M
| $100M | 8.14% | 22,038,773 -1,876,707 | -8% | -$8.52M |
|
4
Keros Therapeutics
KROS
$618M
| $88.5M | 7.2% | 1,523,732 -2,170 | -0.1% | -$126K |
|
|
5
Summit Therapeutics
SMMT
$17.6B
| $23.8M | 1.93% | +1,084,880 | New | +$23.8M |
|
|
6
Corbus Pharmaceuticals
CRBP
$115M
| – | – | -325,140 | Closed | -$14.3M |
|
|
7
Cytokinetics
CYTK
$4.23B
| – | – | -4,575,558 | Closed | -$246M |
|
|
ELEV
8
DELISTED
Elevation Oncology
ELEV
| – | – | -1,916,290 | Closed | -$4.81M |
|
|
9
Avidity Biosciences
RNA
$5.99B
| – | – | -200,000 | Closed | -$8.11M |
|
|
10
Spyre Therapeutics
SYRE
$996M
| – | – | -452,040 | Closed | -$10.3M |
|